Information Provided By:
Fly News Breaks for July 13, 2018
CPRX
Jul 13, 2018 | 07:44 EDT
Oppenheimer analyst Leland Gershell initiated Catalyst Pharmaceuticals with an Outperform rating and $6 price target, telling investors that he sees "smooth FDA sailing" for Firdapse following a surprise setback in 2016, and says Firdapse should start generating revenue for Catalyst by early 2019. Looking ahead, Gershell sees label expansion to congenital myasthenic syndromes in 2020, and clinical data reveals in other ultra-orphan conditions over the next 12-18 months that could catalyse upward revisions to his model.